Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.030
+0.150 (5.21%)
At close: Jun 26, 2026, 4:00 PM EDT
3.060
+0.030 (1.00%)
After-hours: Jun 26, 2026, 6:49 PM EDT
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,529,210
Profits / Employee
$794,951
Market Cap
126.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Fractyl Health | 100 |
| enGene Therapeutics | 82 |
| Verrica Pharmaceuticals | 76 |
| PepGen | 59 |
| Enlivex | 34 |
| Genelux | 26 |
| Spero Therapeutics | 25 |
AGEN News
- 3 days ago - Agenus announces three-year survival data from Phase 1b BOT+BAL study - TheFly
- 3 days ago - Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - Business Wire
- 12 days ago - Agenus Transcript: AGM 2026 - Transcripts
- 25 days ago - Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
- 5 weeks ago - Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - Business Wire
- 5 weeks ago - Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - Business Wire
- 6 weeks ago - Agenus announces publication of Phase 1b BOT+BAL data - TheFly
- 6 weeks ago - Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - Business Wire